COG: AHOD1721 Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (CHL) after Failure of First-Line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
1. R1 (Low Risk) Cohort: To describe event-free survival (EFS) rate at 3 years, as assessed by blinded independent central review without BMT.
2. To describe the complete metabolic response (CMR) rate prior to HDCT/ASCT using Lugano 2014 response criteria
3. To describe the toxicity of nivolumab + brentuximab in combination in pediatric and young adult participants with relapsed or refractory classical Hodgkin s lymphoma (cHL) after failure of first-line treatment.
4. To characterize pharmacokinetics (PK) of nivolumab and brentuximab followingcombination therapy
- Rutgers Cancer Institute of New Jersey
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
- Classic Hodgkin Lymphoma (cHL), relapsed or refractory
- Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for
participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
- One prior anti-cancer therapy that did not work
- Active, known, or suspected autoimmune disease or infection
- Active cerebral/meningeal disease related to the underlying malignancy
- More than one line of anti-cancer therapy or no treatment at all
- Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
- Prior treatment with any drug that targets T cell co-stimulation pathways (such as
Other protocol defined inclusion/exclusion criteria could apply
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.